» Articles » PMID: 19090960

Glomerular Matrix Metalloproteinases and Their Regulators in the Pathogenesis of Lupus Nephritis

Overview
Publisher Biomed Central
Specialty Rheumatology
Date 2008 Dec 19
PMID 19090960
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Lupus nephritis is a major contributor to morbidity and mortality in systemic lupus erythematosus, but little is known about the pathogenic processes that underlie the progressive decay in renal function. A common finding in lupus nephritis is thickening of glomerular basement membranes associated with immune complex deposition. It has been speculated that alterations in the synthesis or degradation of membrane components might contribute to such changes, and thereby to initiation and progression of nephritis through facilitation of immune complex deposition. Matrix metalloproteinases (MMPs) are enzymes that are intimately involved in the turnover of major glomerular basement membrane constituents, including collagen IV and laminins. Alterations in the expression and activity of MMPs have been described in a number of renal diseases, suggesting their relevance to the pathogenesis of various glomerulopathies. The same is true for their natural inhibitors, the tissue inhibitor of metalloproteinase family. Recent data from our group have identified an increase in proteolytic activity within the glomerulus coinciding with the development of proteinuria in the mouse model of systemic lupus erythematosus. (NXB x NZW)F1 Here we review current understanding of MMP/tissue inhibitor of metalloproteinase function within the kidney, and discuss their possible involvement in the development and progression of lupus nephritis.

Citing Articles

Implications of CD154 and Its Receptors in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.

Allard C, Salti S, Mourad W, Hassan G Cells. 2024; 13(19.

PMID: 39404385 PMC: 11482534. DOI: 10.3390/cells13191621.


Matrix metalloproteinases in kidney homeostasis and diseases: an update.

Tan R, Liu Y Am J Physiol Renal Physiol. 2024; 327(6):F967-F984.

PMID: 39361724 PMC: 11687849. DOI: 10.1152/ajprenal.00179.2024.


The Inflammatory Profile Orchestrated by Inducible Nitric Oxide Synthase in Systemic Lupus Erythematosus.

Ene C, Nicolae I J Pers Med. 2023; 13(6).

PMID: 37373923 PMC: 10304544. DOI: 10.3390/jpm13060934.


Dysbiosis in Peripheral Blood Mononuclear Cell Virome Associated With Systemic Lupus Erythematosus.

Guo G, Ye L, Shi X, Yan K, Huang J, Lin K Front Cell Infect Microbiol. 2020; 10:131.

PMID: 32328467 PMC: 7153479. DOI: 10.3389/fcimb.2020.00131.


The clinical utility of gene expression examination in rheumatology.

Tchetina E, Markova G Mediterr J Rheumatol. 2020; 28(3):116-126.

PMID: 32185269 PMC: 7046055. DOI: 10.31138/mjr.28.3.116.


References
1.
Chromek M, Tullus K, Lundahl J, Brauner A . Tissue inhibitor of metalloproteinase 1 activates normal human granulocytes, protects them from apoptosis, and blocks their transmigration during inflammation. Infect Immun. 2003; 72(1):82-8. PMC: 343974. DOI: 10.1128/IAI.72.1.82-88.2004. View

2.
Lenz O, Striker L, Jacot T, Elliot S, Killen P, Striker G . Glomerular endothelial cells synthesize collagens but little gelatinase A and B. J Am Soc Nephrol. 1998; 9(11):2040-7. DOI: 10.1681/ASN.V9112040. View

3.
Guedez L, Stetler-Stevenson W, Wolff L, Wang J, Fukushima P, Mansoor A . In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest. 1998; 102(11):2002-10. PMC: 509153. DOI: 10.1172/JCI2881. View

4.
Gill S, Parks W . Metalloproteinases and their inhibitors: regulators of wound healing. Int J Biochem Cell Biol. 2007; 40(6-7):1334-47. PMC: 2746915. DOI: 10.1016/j.biocel.2007.10.024. View

5.
Zucker S, Mian N, Drews M, Conner C, Davidson A, Miller F . Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity. J Rheumatol. 1999; 26(1):78-80. View